1.Esposito S, Leone S. Antimicrobial treatment for intensive care unit (ICU) infections including the role of the infectious disease specialist. Int J Antimicrob Agents 2007;29:494–500.
2.Bradley JS, Guidos R, Baragona S, et al.Anti-infective research and development-problems, challenges, and solutions. Lancet Infect Dis 2007;7:68–78.
3.Huang SS, Yokoe DS, Hinrichsen VL, et al.Impact of routine intensive care unit surveillance cultures and resultant barrier precautions on hospital-wide mefhicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2006;43:971–978.
4.Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum /3-lactamase production in Enterobac-teriaceae bacteremia: a systematic review and meta-analysis. J Antimicrob Chemother 2007;60:913–920.
5.Chambers HECommunity-associated MRSA-resistance and virulence converge. N Engl J Med 2005;352:1485–1487.
6.Deshpande LM, Fritsche TR, Moet GJ, Biedenbach DJ, Jones RN. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis 2007;58:163–170.
7.Lewis JS 2nd, Herrera M, Wiekes B, Patterson JE, Jorgensen JH. First report of the emergence of CTX-M-type extended-spectrum β-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system. Antimicrob Agents Chemother 2007;51:4015–4021.
8.Moland ES, Hanson ND, Black JA, Hossain A, Song W, Thomson KS. Prevalence of newer β-lactamases in gram-negative clinical isolates collected in the United States from 2001 to 2002. J Clin Microbiol 2006;44:3318–3324.
9.Lockhart SR, Abramson MA, Beekmann SE, et al.Antimicrobial resistance among gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004. J Clin Microbiol 2007;45:3352–3359.
10.Edwards JR, Peterson KD, Andrus ML, et al.National Healthcare Safety Network (NHSN) Report, data summary for 2006, issued June 2007. Am J Infect Control 2007;35:290–301.
12.CLSI. Performance standards for antimicrobial susceptibility testing: 16th informational supplement. CLSI document. Wayne, PA: CLSI, 2008: M100-S18.
13.CLSI. Analysis and presentation of cumulative antimicrobial susceptibility test data: approved guideline. 2nd ed. Wayne, PA: CLSI, 2006:M39-A2.
14.Bradford PA, Bratu S, Urban C, et al.Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 β-lactamases in New York City. Clin Infect Dis 2004;39:55–60.
15.CDC. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1990-May 1999, issued June 1999. Am J Infect Control 1999;27:520–532.
17.Klevens RM, Edwards JR, Tenover FC, McDonald LC, Horan T, Gaynes R; National Nosocomial Infections Surveillance System. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. Clin Infect Dis 2006;42:389–391.
18.National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470–485.
19.Streit JM, Jones RN, Sader HS, Fritsche TR. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). Int J Antimicrob Agents 2004;24:111–118.
20.Stephen JM, Jones RN. Assessment of pathogens and resistance (R) patterns among intensive care unit (ICU) patients in North America (NA): initial report from the SENTRY Antimicrobial Surveillance Program (2001). In: Programs and Abstracts of the 42nd Interscience Congress of Antimicrobial Agents and Chemotherapy American Society for Microbiology; September 27-30, 2002; San Diego, CA. Abstract C2-297.
21.Jones ME, Draghi DC, Thornsberry C, Karlowsky JA, Sahm DF, Wenzel RP. Emerging resistance among bacterial pathogens in the intensive care unit-a European and North American surveillance study (2000-2002). Ann Clin Microbiol Antimicrob 2004;3:14.
22.Fluit AC, Verhoef J, Schmitz FJ. Frequency of isolation and antimicrobial resistance of gram-negative and gram-positive bacteria from patients in intensive care units of 25 European university hospitals participating in the European arm of the SENTRY Antimicrobial Surveillance Program 1997-1998. Eur J Clin Microbiol Infect Dis 2001;20:617–625.
23.Vincent JL, Bihari DJ, Suter PM, et al.The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 1995;274:639–644.
24.Fridkin SK, Steward CD, Edwards JR, et al.Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis 1999;29:245–252.
25.Fridkin SK, Hill HA, Volkova NV, et al.Temporal changes in prevalence of antimicrobial resistance in 23 US hospitals. Emerg Infect Dis 2002;8:697–701.
26.Diekema DJ, Pfaller MA, Jones RN, et al.Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997. Clin Infect Dis 1999;29:595–607.
27.Diekema DJ, Pfaller MA, Jones RN, et al.; SENTRY Participants Group. Trends in antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections in the USA, Canada and Latin America. Int J Antimicrob Agents 2000;13:257–271.
28.Richards C, Emori TG, Edwards J, Fridkin S, Toison J, Gaynes R. Characteristics of hospitals and infection control professionals participating in the National Nosocomial Infections Surveillance System 1999. Am J Infect Control 2001;29:400–403.